ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that has the potential to neutralize all known variants of SARS-CoV-2. The study is evaluating the safety and tolerability of MDX2301 administered via different routes in healthy volunteers and in adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared to conventional monoclonal antibodies.